267 related articles for article (PubMed ID: 22282267)
41. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.
Jayanthan A; Incoronato A; Singh A; Blackmore C; Bernoux D; Lewis V; Stam R; Whitlock JA; Narendran A
Pediatr Blood Cancer; 2011 Mar; 56(3):353-60. PubMed ID: 21225911
[TBL] [Abstract][Full Text] [Related]
42. Clinical features and outcome of MLL gene rearranged acute lymphoblastic leukemia in infants with additional chromosomal abnormalities other than 11q23 translocation.
Tauchi H; Tomizawa D; Eguchi M; Eguchi-Ishimae M; Koh K; Hirayama M; Miyamura N; Kinukawa N; Hayashi Y; Horibe K; Ishii E
Leuk Res; 2008 Oct; 32(10):1523-9. PubMed ID: 18448165
[TBL] [Abstract][Full Text] [Related]
43. The antimicrobial heterodimer S100A8/S100A9 (calprotectin) is upregulated by bacterial flagellin in human epidermal keratinocytes.
Abtin A; Eckhart L; Gläser R; Gmeiner R; Mildner M; Tschachler E
J Invest Dermatol; 2010 Oct; 130(10):2423-30. PubMed ID: 20555353
[TBL] [Abstract][Full Text] [Related]
44. Relatively favorable prognosis for MLL-rearranged childhood acute leukemia with reciprocal translocations.
Yang L; Ding L; Liang J; Chen J; Tang Y; Xue H; Gu L; Shen S; Li B; Chen J
Pediatr Blood Cancer; 2018 Oct; 65(10):e27266. PubMed ID: 29943896
[TBL] [Abstract][Full Text] [Related]
45. Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4
Bardini M; Trentin L; Rizzo F; Vieri M; Savino AM; Garrido Castro P; Fazio G; Van Roon EHJ; Kerstjens M; Smithers N; Prinjha RK; Te Kronnie G; Basso G; Stam RW; Pieters R; Biondi A; Cazzaniga G
Mol Cancer Ther; 2018 Aug; 17(8):1705-1716. PubMed ID: 29748211
[No Abstract] [Full Text] [Related]
46. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells.
Hermani A; De Servi B; Medunjanin S; Tessier PA; Mayer D
Exp Cell Res; 2006 Jan; 312(2):184-97. PubMed ID: 16297907
[TBL] [Abstract][Full Text] [Related]
47. Investigating the extremes of the continuum of paracrine functions in CD34-/CD31+ CACs across diverse populations.
Landers-Ramos RQ; Sapp RM; VandeWater E; Macko J; Robinson S; Wang Y; Chin ER; Spangenburg EE; Prior SJ; Hagberg JM
Am J Physiol Heart Circ Physiol; 2017 Jan; 312(1):H162-H172. PubMed ID: 27793853
[TBL] [Abstract][Full Text] [Related]
48. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.
Zhu Y; He X; Lin YC; Dong H; Zhang L; Chen X; Wang Z; Shen Y; Li M; Wang H; Sun J; Nguyen LX; Zhang H; Jiang W; Yang Y; Chen J; Müschen M; Chen CW; Konopleva MY; Sun W; Jin J; Carlesso N; Marcucci G; Luo Y; Li L
Blood; 2019 Oct; 134(15):1257-1268. PubMed ID: 31395602
[TBL] [Abstract][Full Text] [Related]
49. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
Lopez-Millan B; Sanchéz-Martínez D; Roca-Ho H; Gutiérrez-Agüera F; Molina O; Diaz de la Guardia R; Torres-Ruiz R; Fuster JL; Ballerini P; Suessbier U; Nombela-Arrieta C; Bueno C; Menéndez P
Leukemia; 2019 Jul; 33(7):1557-1569. PubMed ID: 30635633
[TBL] [Abstract][Full Text] [Related]
50. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.
Hilden JM; Dinndorf PA; Meerbaum SO; Sather H; Villaluna D; Heerema NA; McGlennen R; Smith FO; Woods WG; Salzer WL; Johnstone HS; Dreyer Z; Reaman GH;
Blood; 2006 Jul; 108(2):441-51. PubMed ID: 16556894
[TBL] [Abstract][Full Text] [Related]
51. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.
Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381
[TBL] [Abstract][Full Text] [Related]
52. Pathogenic Role of the Damage-Associated Molecular Patterns S100A8 and S100A9 in Coxsackievirus B3-Induced Myocarditis.
Müller I; Vogl T; Pappritz K; Miteva K; Savvatis K; Rohde D; Most P; Lassner D; Pieske B; Kühl U; Van Linthout S; Tschöpe C
Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29158436
[TBL] [Abstract][Full Text] [Related]
53. Relapsed infant MLL-rearranged acute lymphoblastic leukemia with additional genetic alterations.
Ishida H; Kanamitsu K; Washio K; Muraoka M; Sakakibara K; Matsubara T; Kanzaki H; Shimada A
Pediatr Blood Cancer; 2016 Nov; 63(11):2059-60. PubMed ID: 27322816
[No Abstract] [Full Text] [Related]
54. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia.
Pui CH; Behm FG; Downing JR; Hancock ML; Shurtleff SA; Ribeiro RC; Head DR; Mahmoud HH; Sandlund JT; Furman WL
J Clin Oncol; 1994 May; 12(5):909-15. PubMed ID: 8164041
[TBL] [Abstract][Full Text] [Related]
55. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Schneider P; Nollau P; Horstmann M; Beverloo HB; van der Voort E; Valsecchi MG; de Lorenzo P; Sallan SE; Armstrong SA; Pieters R
Blood; 2005 Oct; 106(7):2484-90. PubMed ID: 15956279
[TBL] [Abstract][Full Text] [Related]
56. Advanced glycation end products increase expression of S100A8 and A9 via RAGE-MAPK in rat dental pulp cells.
Nakajima Y; Inagaki Y; Kido J; Nagata T
Oral Dis; 2015 Apr; 21(3):328-34. PubMed ID: 25098709
[TBL] [Abstract][Full Text] [Related]
57. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia.
Stam RW; Schneider P; de Lorenzo P; Valsecchi MG; den Boer ML; Pieters R
Blood; 2007 Oct; 110(7):2774-5. PubMed ID: 17881645
[No Abstract] [Full Text] [Related]
58. Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.
Ando N; Furuichi Y; Kasai S; Tamai M; Harama D; Kagami K; Abe M; Goi K; Inukai T; Sugita K
Leuk Res; 2018 Dec; 75():36-44. PubMed ID: 30453100
[TBL] [Abstract][Full Text] [Related]
59. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
[TBL] [Abstract][Full Text] [Related]
60. Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity.
Inukai T; Zhang X; Goto M; Hirose K; Uno K; Akahane K; Nemoto A; Goi K; Sato H; Takahashi K; Honna H; Kagami K; Nakamoto K; Yagita H; Okumura K; Koyama-Okazaki T; Nakazawa S; Sugita K
Leukemia; 2006 Dec; 20(12):2119-29. PubMed ID: 17066095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
